Company / Free Cash Flow
Arrowhead Pharmaceuticals Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$156.9M
FY2025
5-year range
-$604.3M / $156.9M
FY2021-FY2025
Trend
+126.0%
vs FY2024
Sector context
#37 of 194
Health Care
What the data says
Arrowhead Pharmaceuticals's free cash flow of $157M is higher than 81% of companies in the Health Care sector (FY2025). Free Cash Flow has fluctuated over the past 10 years, ranging from -$604M in FY2024 to $157M in FY2025.
Based on SEC 10-K filings.
$157M in FY2025. Top quartile in the Health Care sector.
Improved from $148M to $157M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 194This company $156.9M Sector average $470.6M
▼
-66.7% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 126.0% year-over-year.
- Ranks #37 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $156.9M | +126.0% |
| FY2024 | -$604.3M | -509.0% |
| FY2023 | $147.7M | +237.1% |
| FY2022 | -$107.8M | -172.9% |
| FY2021 | $147.7M | +237.1% |
| FY2020 | -$107.8M | -238.2% |
| FY2019 | -$31.9M | +53.3% |
| FY2018 | -$68.3M | -0.9% |
| FY2017 | -$67.7M | +0.9% |
| FY2016 | -$68.3M | -253.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026